COO of Novocure (30-Year Financial, Insider Trades) Michael J. Ambrogi (insider trades) sold 11,647 shares of NVCR on 02/25/2020 at an average price of $81.16 a share. The total sale was $945,271.
NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors. NovoCure Ltd has a market cap of $7.86 billion; its shares were traded at around $79.46 with and P/S ratio of 24.23. NovoCure Ltd had annual average EBITDA growth of 26.40% over the past five years.
CFO Recent Trades:
- CFO Wilhelmus Cm Groenhuysen sold 18,908 shares of NVCR stock on 02/25/2020 at the average price of $81.16. The price of the stock has decreased by 2.09% since.
Directors and Officers Recent Trades:
- General Counsel Todd Christopher Longsworth sold 8,482 shares of NVCR stock on 02/25/2020 at the average price of $81.16. The price of the stock has decreased by 2.09% since.
- COO Michael J. Ambrogi sold 11,647 shares of NVCR stock on 02/25/2020 at the average price of $81.16. The price of the stock has decreased by 2.09% since.
For the complete insider trading history of NVCR, click here
.
